MYB regulates the DNA damage response and components of the homology-directed repair pathway in human estrogen receptor-positive breast cancer cells

被引:0
|
作者
Ren-Ming Yang
Devathri Nanayakkara
Murugan Kalimutho
Partha Mitra
Kum Kum Khanna
Eloise Dray
Thomas J. Gonda
机构
[1] University of Queensland,School of Pharmacy
[2] QIMR Berghofer Medical Research Institute,Signal Transduction Laboratory
[3] QUT at the Translational Research Institute,Institute of Health and Biomedical Innovations
[4] Mater Research/UQ at the Translational Research Institute,Keck School of Medicine at the Children’s Hospital Los Angeles Campus
[5] University of South Australia Cancer Research Institute,Institute of Health and Biomedical Innovation
[6] University of Southern California,undefined
[7] Queensland University of Technology,undefined
[8] University of Texas Health,undefined
[9] San Antonio,undefined
[10] Department of Biochemistry and Structural Biology,undefined
来源
Oncogene | 2019年 / 38卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Over 70% of human breast cancers are estrogen receptor-positive (ER+), most of which express MYB. In these and other cell types, the MYB transcription factor regulates the expression of many genes involved in cell proliferation, differentiation, tumorigenesis, and apoptosis. So far, no clear link has been established between MYB and the DNA damage response in breast cancer. Here, we found that silencing MYB in the ER+ breast cancer cell line MCF-7 led to increased DNA damage accumulation, as marked by increased γ-H2AX foci following induction of double-stranded breaks. We further found that this was likely mediated by decreased homologous recombination-mediated repair (HRR), since silencing MYB impaired the formation of RAD51 foci in response to DNA damage. Moreover, cells depleted for MYB exhibited reduced expression of several key genes involved in HRR including BRCA1, PALB2, and TOPBP1. Taken together, these data imply that MYB and its targets play an important role in the response of ER+ breast cancer cells to DNA damage, and suggest that induction of DNA damage along with inhibition of MYB activity could offer therapeutic benefits for ER+ breast cancer and possibly other cancer types.
引用
下载
收藏
页码:5239 / 5249
页数:10
相关论文
共 50 条
  • [21] The kinome associated with estrogen receptor-positive status in human breast cancer
    Bruce, M. Christine
    McAllister, Danielle
    Murphy, Leigh C.
    ENDOCRINE-RELATED CANCER, 2014, 21 (05) : R357 - R370
  • [22] Testing Endocrine Response for Managing Primary Estrogen Receptor-Positive Breast Cancer
    Dowsett, Mitch
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (23) : 2520 - +
  • [23] In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer
    Bennink, RJ
    van Tienhoven, G
    Rijks, LJ
    Noorduyn, AL
    Janssen, AG
    Sloof, GW
    JOURNAL OF NUCLEAR MEDICINE, 2004, 45 (01) : 1 - 7
  • [24] Predictors of response to neoadjuvant chemotherapy in estrogen receptor-positive breast cancer.
    Moore, Halle C. F.
    Maiti, Baidehi
    Rybicki, Lisa A.
    Booth, Christine
    Abraham, Jame
    Budd, G. Thomas
    Andresen, Steven Ware
    Downs-Kelly, Erinn
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer
    Simigdala, Nikiana
    Gao, Qiong
    Pancholi, Sunil
    Roberg-Larsen, Hanne
    Zvelebil, Marketa
    Ribas, Ricardo
    Folkerd, Elizabeth
    Thompson, Andrew
    Bhamra, Amandeep
    Dowsett, Mitch
    Martin, Lesley-Ann
    BREAST CANCER RESEARCH, 2016, 18
  • [26] A localized nucleolar DNA damage response facilitates recruitment of the homology-directed repair machinery independent of cell cycle stage
    van Sluis, Marjolein
    McStay, Brian
    GENES & DEVELOPMENT, 2015, 29 (11) : 1151 - 1163
  • [27] Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer
    Nikiana Simigdala
    Qiong Gao
    Sunil Pancholi
    Hanne Roberg-Larsen
    Marketa Zvelebil
    Ricardo Ribas
    Elizabeth Folkerd
    Andrew Thompson
    Amandeep Bhamra
    Mitch Dowsett
    Lesley-Ann Martin
    Breast Cancer Research, 18
  • [28] Estrogen and TCDD Influence RLN2 Gene Activity in Estrogen Receptor-Positive Human Breast Cancer Cells
    Kietz, Silke
    Feng, Shu
    Agoulnik, Alexander
    Hombach-Klonisch, Sabine
    RELAXIN AND RELATED PEPTIDES: FIFTH INTERNATIONAL CONFERENCE, 2009, 1160 : 367 - 373
  • [29] Different anticancer effects of Saxifragifolin A on estrogen receptor-positive and estrogen receptor-negative breast cancer cells
    Kim, Kyung-Ho
    Kim, Ji-Yun
    Kwak, Jong-Hwan
    Pyo, Suhkneung
    PHYTOMEDICINE, 2015, 22 (09) : 820 - 828
  • [30] Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
    Bostner, Josefine
    Alayev, Anya
    Berman, Adi Y.
    Fornander, Tommy
    Nordenskjold, Bo
    Holz, Marina K.
    Stal, Olle
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 17 - 27